The results on 40,000+ mammograms showed that if Mia is introduced, the overall double reading recall rate is 4-5% and the cancer detection rate is 8.4 per 1000.
The next generation decision-support tool aims to restore an evidence-based approach to molecular diagnostics and oncology.
The new service enables patients, anywhere in the world, to access treatment options across a network of cancer centers without leaving home.
Acquisition will bring together two companies committed to improving the lives of cancer patients through the evolving field of health data and analytics.
Under the deal, Accenture will provide digital data integration services to Roche's NAVIFY Tumor Board solution.
Called BiliScreen, it relies on computer vision algorithms and machine learning tools to detect increased bilirubin levels in a person's sclera.
The Sunface app photoages the user's skin based on skin type and individual UV-protection behavior.
The device uses two hundred small tactile biosensors that map the surface of the breast and monitor changes in texture, color and temperature.
One of the app features helps to manage, and track appointments, treatments, goals, tips, information, and what has worked for others in similar situations.
The Breast Cancer Weight Loss (BWEL) study will enroll nearly 3,200 overweight and obese women with early stage breast cancer.